PFMT Educational Intervention for Patients With Advancer Breast Cancer

Status Recruiting

Clinical Trial Summary

A PFMT educational intervention was designed for women with metastasic breast cancer. It consisted in a 120 min workshop and 8 weeks of non-supervised (but with follow-up) self-training. ICIQ, IQOL and ad hoc questions were performed before the workshop and after the 8 weeks training to see the prevalence of UI, the impact in their quality of life and the empowerment of self-training.

Clinical Trial Description

Urinary incontinence (UI) affects women of all ages and has a great impact on the quality of life. Cancer treatments such as chemotherapy or hormone therapy may play an important rol in the development and worsening of pelvic floor disorders. Little evidence on the prevalence and impact of UI in metastassis breast cancer women is known. A protocol was designed to analyze the effect of a PFMT educational intervention on the UI and the impact on the QoL, as well as in the empowerment feeling of the participants. Feasibility of the protocol will be analized to design an optimal RCT for testing our hypothesis During the usual visits, oncologist wil recruit women with advanced breast cancer who meet the inclusion criteria for the participation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04953377
Study type	Interventional
Source	Onkologikoa
Contact	Mireia Pelaez, PhD
Phone	+34943838284
Email	mpelaez@onkologikoa.org
Status	Recruiting
Phase	N/A
Start date	September 2, 2021
Completion date	April 10, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04653740` - Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer	N/A
Completed	`NCT02091960` - A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer	Phase 2
Recruiting	`NCT05156619` - Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
Recruiting	`NCT05173103` - Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
Withdrawn	`NCT05191004` - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC	Phase 1/Phase 2
Completed	`NCT00754325` - Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor	Phase 2
Completed	`NCT03240224` - Bioinformation Therapy for Breast Cancer	Phase 2/Phase 3
Recruiting	`NCT06193525` - FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test	Phase 2
Completed	`NCT03312738` - A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor	Phase 2
Active, not recruiting	`NCT05063786` - Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)	Phase 3
Recruiting	`NCT05655598` - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer	Phase 1
Active, not recruiting	`NCT02499146` - Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer	Phase 1
Completed	`NCT00445458` - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT04456855` - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Completed	`NCT04408118` - First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC	Phase 2
Recruiting	`NCT04222413` - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors	Phase 1
Completed	`NCT03205761` - Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer	Phase 2
Withdrawn	`NCT04316169` - Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer	Phase 1
Completed	`NCT00546104` - Phase II Dasatinib Study in Advanced Breast Cancer	Phase 2
Completed	`NCT00387907` - Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer	Phase 2